Engineered immune cells join forces with targeted drug to fight Hard-to-Treat breast cancer
NCT ID NCT07553390
First seen Apr 29, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This early-phase trial tests a new combination treatment for people with advanced breast cancer that has not responded to standard therapies. The treatment uses specially engineered immune cells (TRICK-NK) plus a targeted drug called T-Dxd. The study aims to find the safest dose and see if the combination can help control the disease. About 60 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UT MD Anderson
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (TRICK-NK) and trastuzumab deruxtecan (T-Dxd)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced breast cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 60 participants, so it is primarily testing safety and dosing. The combination may not control the disease, and side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.